000120384 001__ 120384
000120384 005__ 20240228135019.0
000120384 0247_ $$2doi$$a10.1093/annonc/mdt511
000120384 0247_ $$2pmid$$apmid:24356631
000120384 0247_ $$2ISSN$$a0923-7534
000120384 0247_ $$2ISSN$$a1569-8041
000120384 0247_ $$2altmetric$$aaltmetric:2234266
000120384 037__ $$aDKFZ-2017-00817
000120384 041__ $$aeng
000120384 082__ $$a610
000120384 1001_ $$aHerth, I.$$b0
000120384 245__ $$aThe impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison.
000120384 260__ $$aOxford$$bOxford Univ. Press$$c2014
000120384 3367_ $$2DRIVER$$aarticle
000120384 3367_ $$2DataCite$$aOutput Types/Journal article
000120384 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1520592729_3333
000120384 3367_ $$2BibTeX$$aARTICLE
000120384 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120384 3367_ $$00$$2EndNote$$aJournal Article
000120384 520__ $$aIn a single-center retrospective donor versus no-donor comparison, we investigated if allogeneic stem cell transplantation (alloSCT) can improve the dismal course of poor-risk chronic lymphocytic leukemia (CLL).All patients with CLL who were referred for evaluation of alloSCT within a 7-year time frame and had a donor search indication according to the EBMT criteria or because of Richter's transformation were included. Patients for whom a matched donor could be found within 3 months (matches) were compared with patients without such a donor (controls). Primary end point was overall survival measured from the 3-month landmark after search initiation.Of 105 patients with donor search, 97 (matches 83; controls 14) were assessable at the 3-month landmark. Matches and controls were comparable for age, gender, time from diagnosis, number of previous regimens, and remission status. Disregarding if alloSCT was actually carried out or not, survival from the 3-month landmark was significantly better in matches versus controls [hazard ratio 0.38, 95% confidence interval (CI) 0.17-0.85; P = 0.014]. The survival benefit of matches remained significant on multivariate analysis.This study provides first comparative evidence that alloSCT may have the potential to improve the natural course of poor-risk CLL as defined by the EBMT criteria.
000120384 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000120384 588__ $$aDataset connected to CrossRef, PubMed,
000120384 7001_ $$0P:(DE-He78)6333b389d0abc96ef7f2f6e049a8f8c4$$aDietrich, Sascha$$b1$$udkfz
000120384 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b2$$udkfz
000120384 7001_ $$aHegenbart, U.$$b3
000120384 7001_ $$aRieger, M.$$b4
000120384 7001_ $$aStadtherr, P.$$b5
000120384 7001_ $$aBondong, A.$$b6
000120384 7001_ $$aTran, T. H.$$b7
000120384 7001_ $$aWeide, R.$$b8
000120384 7001_ $$aHensel, M.$$b9
000120384 7001_ $$aKnauf, W.$$b10
000120384 7001_ $$aFranz-Werner, J.$$b11
000120384 7001_ $$aWelslau, M.$$b12
000120384 7001_ $$aProcaccianti, M.$$b13
000120384 7001_ $$aGörner, M.$$b14
000120384 7001_ $$aMeissner, J.$$b15
000120384 7001_ $$aLuft, T.$$b16
000120384 7001_ $$aSchönland, S.$$b17
000120384 7001_ $$aWitzens-Harig, M.$$b18
000120384 7001_ $$0P:(DE-He78)f3d5f16b49eb47520def635be98d5576$$aZenz, Thorsten$$b19$$udkfz
000120384 7001_ $$aHo, A. D.$$b20
000120384 7001_ $$aDreger, P.$$b21
000120384 773__ $$0PERI:(DE-600)2003498-2$$a10.1093/annonc/mdt511$$gVol. 25, no. 1, p. 200 - 206$$n1$$p200 - 206$$tAnnals of oncology$$v25$$x1569-8041$$y2014
000120384 909CO $$ooai:inrepo02.dkfz.de:120384$$pVDB
000120384 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)6333b389d0abc96ef7f2f6e049a8f8c4$$aExternal Institute$$b1$$kExtern
000120384 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000120384 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f3d5f16b49eb47520def635be98d5576$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000120384 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000120384 9141_ $$y2014
000120384 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000120384 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000120384 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120384 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120384 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120384 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN ONCOL : 2015
000120384 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000120384 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000120384 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120384 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120384 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120384 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120384 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120384 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bANN ONCOL : 2015
000120384 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000120384 9201_ $$0I:(DE-He78)G100-20160331$$kG100$$lTranslationale Onkologie$$x1
000120384 980__ $$ajournal
000120384 980__ $$aVDB
000120384 980__ $$aI:(DE-He78)C060-20160331
000120384 980__ $$aI:(DE-He78)G100-20160331
000120384 980__ $$aUNRESTRICTED